Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD)

30 października 2026 zaktualizowane przez: Jing Chen, University of Texas Southwestern Medical Center

REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)

This pilot randomized, open-label, outcome blinded clinical trial is to evaluate the preliminary effects of low-dose Colchicine (LoDoCo) on coronary artery calcification (CAC) progression in adults with chronic kidney disease (CKD) and existing coronary artery calcification. Sixty participants will be randomized 1:1 to received LoDoCo plus usual care or usual care lone and followed for 24 months.

The primary objective is to evaluate the effect of LoDoCo on CAC progression measured by ECG-gates noncontrast cardiac computed tomography (CT). Exploratory outcomes include valvular calcification, bone mineral density, inflammatory, vascular, and miner-bone biomarkers, cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures, kidney biomarkers, and participant-reported measures of treatment acceptability, adherence, and adverse effects.

Przegląd badań

Szczegółowy opis

The investigators will conduct a randomized, open-label, outcome-blinded, clinical trial in 60 adults with chronic kidney disease (CKD) and existing coronary artery calcification (CAC) Agatston scores of ≥100-1000. Participants will be randomized 1:1 to receive low-dose Colchicine (LoDoCo) plus usual care or usual care alone for 24 months.

The primary objective is to evaluate the effect of LoDoCo on CAC progression over 24 months. CAC will be assessed by ECG-gated noncontrast cardiac computed tomography (CT). Outcomes will include Agatston score and calcium volume. The study will estimate variance, baseline-to-follow-up correlations, and other parameters needed to inform future sample size, treatment duration, and endpoint selection.

Exploratory objectives include evaluating the effects of LoDoCo on aortic valve and mitral annular calcification, CT-derived vertebral bone mineral density, inflammatory biomarkers, vascular calcification biomarkers, and miner-bone metabolism biomarkers. Additional exploratory analyses will examine cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures including ankle-brachial index (ABI) and toe-brachial index (TBI), and kidney outcomes including albumin-creatine ratio (uACR) and estimated glomerular filtration rate (eGFR).

Participant experience with LoDoCo will also be evaluated through assessment of treatment acceptability, adherence, adverse effects, and barriers and facilitators to study participation and retention.

Participants will be followed at baseline, 6 months, 12 months, 18 months, and 24 months for data collection. Participants assigned to the intervention group will undergo additional safety monitoring, including laboratory assessments, throughout the study period.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

60

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

30 lat do 69 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Men and women aged 30-<70 years of all race/ethnicity groups
  • Chronic kidney disease (CKD) stage 3 (estimated glomerular filtration rate (eGFR) 30 to <60 ml/min/1.73m2) or eGFR ≥60 and Urine albumin-to-creatinine ratio (uACR) ≥ 30 mg/g
  • Cardiac artery calcification (CAC) Agatston score ≥100-1000
  • Ability to provide informed consent.

Exclusion Criteria:

  • Current Colchicine therapy
  • Hepatic disease
  • Established peripheral arterial disease (PAD) defined by self-report or ICD-10 codes
  • Congestive heart failure classified as New York Heart Association (NYHA) Functional class III or IV
  • Uncontrolled atrial fibrillation with resting heart rate > 100 beats/min
  • Dementia defined by self-report or ICD-10 codes (F01-F03)
  • Alzheimer's disease defined by self-report or ICD-10 codes (G30)
  • Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.
  • Immunosuppression, including the use of immunosuppressive medications
  • Current use of chemotherapy drugs or active cancer
  • Pregnancy/breastfeeding
  • Hospitalized within the past 6 months
  • Allergic/intolerance to colchicine
  • Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir/ritonavir, Saquinavir, Nelfinavir)
  • Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)
  • Human immunodeficiency virus (HIV) infection
  • Gout attack ≥ 1 time per year
  • Severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men)
  • eGFR <30 ml/min/1.73m2
  • White blood cell count (WBC) <3.0 x10^9/L
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x Upper Limit of Normal (ULN)
  • Total bilirubin >2 x ULN
  • Glucose >300mg/dL
  • Uses recreational drugs
  • Participant in other conflict clinical trial
  • Unable to complete the study measurements
  • Unable to undergo to computed tomography (CT)
  • Unsafe to participate in this study per investigator's judgement
  • Unable to read and speak English or Spanish

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Low-Dose Colchicine (LoDoCo)

Participants will receive low-dose Colchicine (LoDoCo) in addition to usual care.

Intervention group will receive LoDoCo (Colchicine 0.5mg), oral, once daily.

Inne nazwy:
  • LoDoCo

Participants will receive usual care according to standard clinical practice and treating physician discretion.

Aktywny komparator: Usual Care

Participants will receive usual care alone.

Participants will receive usual care according to standard clinical practice and treating physician discretion.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in Coronary Artery Calcification Agatston Scores
Ramy czasowe: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Coronary artery calcification will be quantified using the Coronary Artery Calcium (CAC) Agatston Score. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Change in Coronary Artery Calcification Volume Scores
Ramy czasowe: Baseline, 12 months, 24 months

Change in Coronary Artery Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Exploratory: Change in Aortic Valve Calcification Agatston Scores
Ramy czasowe: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Aortic valve calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the aortic valve. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Aortic Valve Calcification Volume Scores
Ramy czasowe: Baseline, 12 months, 24 months

Change in Aortic Valve Calcification volume (mm3) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Agatston Scores
Ramy czasowe: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Mitral annular calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the mitral valve annulus. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Volume Scores
Ramy czasowe: Baseline, 12 months, 24 months

Change in Mitral Annular Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months
Exploratory: Change in Vertebral Bone Mineral Density (BMD)
Ramy czasowe: Baseline, 12 months, 24 months

Change in vertebral BMD (mg/cm³) will be measured from ECG-gated non-contrast computer tomography (CT) using validated CT-based densitometry methods. BMD will be quantified within the vertebral bodies. Vertebral MBD values range from <80mg/cm³ (very low), 80-120mg/cm³ (low), and >120 mg/cm³ (normal). Lower TBI values are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in C-Reactive Protein (CRP) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating CRP (mg/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-1 beta (IL-1β) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating IL-1β levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-6 (IL-6) Levels
Ramy czasowe: Baseline, 12 months, 18 months

Circulating IL-6 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 18 months
Exploratory: Change in Interleukin-18 (IL-18) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating IL-18 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Tumor Necrosis Factor alpha
Ramy czasowe: Baseline, 12 months, 24 months

Circulating TNF-a levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-17 (IL-17) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating IL-17 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Monocyte Chemoattractant Protein-1 (MCP-1) levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating MCP-1 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Klotho Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating klotho levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Fetuin A Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating fetuin A levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Osteopontin Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating osteopontin levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-2 (BMP-2) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating BMP-2 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-4 (BMP-4) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating BMP-4 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-7 (BMP-7) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating BMP-7 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Phosphate levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating serum phosphate levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Calcium Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating serum calcium levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Parathyroid Hormone (PTH) levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating PTH levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone-Specific Alkaline Phosphatase (BSAP) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating serum BSAP levels (ug/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Fibroblast Growth Factor 23 (FGF23) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating FGF23 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Wnt Inhibitory Factor-1 Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating Wnt Inhibitory Factor-1 (pg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Intact N-Terminal Propeptide of Type I Procollagen (P1NP) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating P1NP levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Sclerostin Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating sclerostin levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Tartrate-Resistant Acid Phosphatase 5b (TRAP-5b) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating TRAP-5b levels (U/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in National Institutes of Health (NIH) Toolbox Fluid Cognition Composite Standard Score
Ramy czasowe: Baseline, 12 months, 24 months

The NIH Toolbox Fluid Cognition Composite score assesses cognitive functions involved in processing and responding to new information, including attention, executive function, episodic memory, processing speed, and working memory. The age-adjusted Fluid Cognition Composite Standard Score is derived from participant performance on NIH Toolbox cognitive assessments and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Scores of 70 or lower indicate significant impairment, scores around 85 are below average, scores around 100 are average, scores around 115 are above average, and scores around 130 are superior. Higher scores indicate better cognitive performance.

Baseline, 12 months, 24 months
Exploratory: Change in Executive Function
Ramy czasowe: Baseline, 12 months, 24 months

Executive function will be assessed using the NIH Toolbox Dimensional Change Card Sort Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better executive functioning.

Baseline, 12 months, 24 months
Exploratory: Change in Attention/Inhibitory Control
Ramy czasowe: Baseline, 12 months, 24 months

Attention and inhibitory control will be assessed using the NIH Toolbox Flanker Inhibitory Control Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better attention and inhibitory control.

Baseline, 12 months, 24 months
Exploratory: Change in Processing Speed
Ramy czasowe: Baseline, 12 months, 24 months

Processing speed will be assessed using the NIH Toolbox Pattern Comparison Processing Speed test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better processing speed.

Baseline, 12 months, 24 months
Exploratory: Change in Working Memory
Ramy czasowe: Baseline, 12 months, 24 months

Working memory will be assessed using the NIH Toolbox List Sorting Working Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better working memory.

Baseline, 12 months, 24 months
Exploratory: Change in Episodic Memory
Ramy czasowe: Baseline, 12 months, 24 months

Episodic memory will be assessed using the NIH Toolbox Picture Sequence Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better episodic memory.

Baseline, 12 months, 24 months
Exploratory: Change in Language/Vocabulary
Ramy czasowe: Baseline, 12 months, 24 months

Language/Vocabulary will be assessed using the NIH Toolbox Picture Vocabulary Test and Oral Reading Recognition tests. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better language ability.

Baseline, 12 months, 24 months
Exploratory: Change in Southwestern Assessment of Processing Speed (SWAPS) Score
Ramy czasowe: Baseline, 12 months, 24 months

The SWAPS will be used to assess processing speed. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better processing speed performance.

Baseline, 12 months, 24 months
Exploratory: Change in Texas Card Sorting Test (TCST) Score
Ramy czasowe: Baseline, 12 months, 24 months

The TCST will be used to assess executive functioning, including cognitive flexibility and concept formation. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better executive functioning.

Baseline, 12 months, 24 months
Exploratory: Change in Phosphorylated tau 217 (p-tau217) levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating p-tau217 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Amyloid-beta 42/40 ratio (Aβ42/40) Levels
Ramy czasowe: Baseline, 12 months, 24 months

Circulating Aβ42 and Aβ40 levels (pg/mL) will be measured using standard clinical laboratory assays and the Aβ42/40 ratio calculated from these measurements and reported as a unitless ratio.

Baseline, 12 months, 24 months
Exploratory: Change in Ankle-Brachial Index (ABI)
Ramy czasowe: Baseline, 12 months, 24 months

ABI will be measured using semi-automated validated device (simpleABI-600CL). ABI values range from ≤0.90 (Peripheral artery disease), 0.91-0.99 (borderline), 1.00-1.40 (normal).ABI values >1.40 indicate non-compressible arteries, suggestive of arterial stiffness or medial calcification. Both ABI values ≤0.90 and >1.40 are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Toe-Brachial Index (TBI)
Ramy czasowe: Baseline, 12 months, 24 months

TBI will be measured using semi-automated validated device (simpleABI-600CL). TBI values range from ≥0.70 (normal), 0.64-0.69 (borderline), and <0.40-0.50 (severe distal arterial disease/critical ischemia range). TBI values <0.70 is a commonly used threshold suggestive of peripheral artery disease. Lower TBI values are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Percentage of Participants with Ankle-Brachial Index (ABI) ≤0.9 or >1.4
Ramy czasowe: Baseline, 12 months, 24 months

ABI will be measured using semi-automated validated device (simpleABI-600CL). The percentage (%) of participants with an ABI ≤0.9, indicative of peripheral arterial disease, or an ABI >1.4, indicative of non-compressible arteries suggestive of arterial stiffness or medial calcification will be determined. Higher percentages indicate a greater proportion of participants with abnormal ABI findings.

Baseline, 12 months, 24 months
Exploratory: Change in Urine Albumin-to-Creatine Ratio (uACR)
Ramy czasowe: Baseline, 12 months, 24 months

Circulating urinary albumin and creatine levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Estimated Glomerular Filtration Rate (eGFR)
Ramy czasowe: Baseline, 12 months, 24 months

eGFR values (mL/min/1.73m2) will be calculated using the NKF-ASN CKD-Epi refit formula.

Baseline, 12 months, 24 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Jing Chen, MD, University of Texas

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

30 października 2026

Zakończenie podstawowe (Szacowany)

1 maja 2029

Ukończenie studiów (Szacowany)

1 maja 2029

Daty rejestracji na studia

Pierwszy przesłany

11 czerwca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

11 czerwca 2026

Pierwszy wysłany (Rzeczywisty)

17 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

4 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

30 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

IRB approval is required before sharing IPD.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Tak

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj